AccueilAVDL • NASDAQ
add
Flamel technologies
Dernière clôture
7,90Â $
Variation sur la journée
7,80Â $ - 8,35Â $
Plage sur l'année
7,39Â $ - 19,09Â $
Capitalisation boursière
761,26Â M USD
Volume moyen
1,33Â M
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
(USD) | sept. 2024info | Variation Y/Y |
---|---|---|
Chiffre d'affaires | 50,02Â M | 613,22Â % |
Charges d'exploitation | 44,20Â M | 5,21Â % |
Résultat net | -2,62 M | 92,76 % |
Marge bénéficiaire nette | -5,25 | 98,98 % |
Bénéfice par action | -0,03 | 92,68 % |
EBITDA | 708,00Â k | 102,05Â % |
Taux d'imposition effectif | -3,47 % | — |
Bilan
Total des actifs
Total du passif
(USD) | sept. 2024info | Variation Y/Y |
---|---|---|
Trésorerie/Invest. court terme | 65,81 M | -57,04 % |
Total des actifs | 158,25Â M | -22,08Â % |
Total du passif | 83,59Â M | -10,07Â % |
Total des capitaux propres | 74,66 M | — |
Actions en circulation | 96,36 M | — |
Ratio cours/valeur comptable | 10,13 | — |
Rentabilité des actifs | -0,52 % | — |
Retour sur capitaux | -0,73 % | — |
Flux de trésorerie
Variation nette en trésorerie
(USD) | sept. 2024info | Variation Y/Y |
---|---|---|
Résultat net | -2,62 M | 92,76 % |
Trésorerie (opérations) | -6,89 M | 81,98 % |
Trésorerie (invest.) | 4,93 M | -49,80 % |
Trésorerie (financement) | 1,18 M | -96,14 % |
Variation nette en trésorerie | -265,00 k | -114,51 % |
Flux de trésorerie dispo. | -9,99 M | 64,96 % |
À propos
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Date de fondation
1990
Site Web
Employés
154